All In Biotech

Drug Trial Radar · NCT06280144

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Live Attenuated Influenza Vaccine in People Aged 3-17

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 6,080 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

6,080

Planned (sponsor's estimate)

Start

Sep 22, 2023

Primary completion

Jun 30, 2024

Study completion Oct 30, 2024

Sponsor

Sponsor type
Industry
Collaborators
Hu Bei province Center for Disease control and prevention; The Inner Mongolia Autonomous Region Center for Disease Control and Prevention
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.

Conditions

  • Influenza Prevention

Interventions

  • Influenza Vaccine, Live, Nasal, Freeze-driedBiological

    The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50

  • Sterile water for inhalationOther

    Sterile water for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary influenza protective effect endpointTime frame: 7 months
  2. Primary influenza protective effect endpointTime frame: 7 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chifeng, Inner Mongolia, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.